Research at Oslo University Hospital

 

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

 

Latest news

Nominating outstanding scientists, closing date March 1st:

Excellent Researcher Award and Early Career Award 2018

 
From the 2017 ceremony. From left: J. Hov, K. Sandvig and T.P. Utheim.
From the 2017 ceremony. From left: J. Hov, K. Sandvig and T.P. Utheim.

Oslo University Hospital announce research awards in the following categories for 2018:

  • Excellent Researcher Award (300.000 NOK)
  • Early Career Award (two prizes of 150.000 NOK)

The candidates must be employed by Oslo University Hospital or University of Oslo, and member of a research group at one of these institutions.

 
 

Popular science dissemination of cancer genomics

 

Research from the Department of Molecular Oncology has recently been profiled in three popular science articles.

In an interview in Apollon, Rolf Skotheim discusses why some healthy cells turn into cancer cells.

Bjarne Johannessen and Kaja C. G. Berg have written about colorectal cancer cell lines in the magazine BestPractice. BestPractice is a Norwegian medical journal which focuses on oncology and hematology.

In the same journal, Anita Sveen has written about tumor heterogeneity in metastatic colorectal cancer.

 
 

Cell therapy research presented in national newspaper VG

 

Research on immunotherapy conducted at the Department of Oncology is presented in a feature article in the popular national Norwegian newspaper Verdens Gang (VG) January 9th. The article focuses on recent progress in chimeric antigen receptor (CAR) T cell therapy. For two years, children with leukemia and adults with lymphoma has been treated through clinical studies. Now the project will be expanded with three new studies on lymphomas.

 
 

Preclinical drug screening identifies novel stratified treatment options according to the consensus molecular subtypes of colorectal cancer

 
From left: Anita Sveen, Jarle Bruun and Peter W. Eide.
From left: Anita Sveen, Jarle Bruun and Peter W. Eide.

In two recent publications (Eide PW et al. Sci Rep; Sveen A*, Bruun J* et al. Clin Cancer Res), scientists in the Lothe lab., Department of Molecular Oncology, have identified novel potential treatment strategies for colorectal cancer (CRC), guided by the consensus molecular subtypes (CMS). Combining algorithm development, for translation of CMS classification to preclinical models, with drug screening of classified cell lines and patient-derived xenografts (PDXs) in collaboration with the Finnish Institute for Molecular Medicine and Vall d´Hebron Institute of Oncology, a potential to overcome chemoresistance in the poor prognostic CMS4-mesenchymal group was identified by combination therapy with 5-fluorouracil (5-FU) and HSP90 inhibitors.

 
 

The discovery of TIGIT as a potential new target for immune checkpoint blockade is published in Clinical Cancer Research.

 
From left: Kanutte Huse, Sarah Josefsson and June Myklebust
From left: Kanutte Huse, Sarah Josefsson and June Myklebust

Biological advances have resulted in immunotherapeutic regimens that target co-inhibitory receptors such as PD-1 to reverse T-cell exhaustion and promote anti-tumor responses that eradicate human tumors. However, despite its success in many cancer types, a substantial number of patients do not respond to PD-1/PD-L1 blockade. This includes patients with the B-cell malignancy follicular lymphoma, suggesting that co-blockade of co-inhibitory receptors may be necessary to achieve optimal anti-tumor T-cell responses.
In a study recently published in Clinical Cancer Research (journal impact factor 9.6), the authors demonstrate the power of using high dimensional flow cytometry analysis of follicular lymphoma tumors to identify new targets for checkpoint blockade.

 
 

Scientists from the Research Institute of Internal Medicine receive funding from ERA-Net

 
From left: Arne Yndestad, Pål Aukrust and Bente Halvorsen
From left: Arne Yndestad, Pål Aukrust and Bente Halvorsen

Professor Pål Aukrust has together with senior scientist dr. Arne Yndestad and professor Bente Halvorsen received ERA-NET funding on cardiovascular diseases (ERA-CVD). All three scientists are affiliated Research Institute of Internal Medicine at the Division of Surgery, Inflammatory Medicine and Transplantation (“KIT”), Oslo University Hospital and Institute of Clinical Medicine, University of Oslo.

The funding, amounting to 2.4 mill NOK over a period of three years, is based on a collaborative project with professor Joachim Schultze, Bonn, Germany, professor Michael Sieweki, Marseille, France, and professor Erik A Biessen, Maastricht, The Netherlands, who is heading the consortium. The project named AtheroMacHete (Atherosclerosis Macrophage Heterogeneity study) will particular focus on intra plaque macrophage heterogeneity in patients with atherosclerotic disorders and experimental model systems.

 
 

Oslo University Hospital has awarded 6 excellent articles for the first half-year of 2017

 
Award winners during the ceremony (photo Pål Bakke)
Award winners during the ceremony (photo Pål Bakke)

Six research groups were awarded for their excellent papers published during the first half-year of 2017 during a ceremony on December 16th. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.

The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.

 
 

Per Steinar Halvorsen appointed "Innovator of the Month" by Helse Sør-Øst

 
Per S.Halvorsen(photo: Hedda Holth)
Per S.Halvorsen
(photo: Hedda Holth)

Per Steinar Halvorsen, head of the "Clinical and experimental cardiovascular monitoring" research group at the Intervention Centre at the Division of Emergencies and Clinical Care, was appointed "Innovator of the Month" for the month of October by South-Eastern Norway Regional Health Authority (Helse Sør-Øst).
His work is presented in an article (in Norwegian) entitled "Pacemaker of the future", published on the home page of Helse Sør-Øst.

 
 

Press release – 29 Nov 2017

The Laboratory of Adaptive Immunity and Homeostasis enters a strategic research collaboration with a leading pharmaceutical company

 
Jan T. Andersen (photo: UiO/Ø.H. Horgmo)
Jan T. Andersen (photo: UiO/Ø.H. Horgmo)

The Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, at Oslo University Hospital and University of Oslo, is combining structural and biophysical approaches with cellular and animal studies to unravel how the neonatal Fc receptor (FcRn) acts as a key player in regulation of the long serum half-life of albumin and IgG antibodies. The research group has signed a strategic research agreement with Roche Diagnostics GmbH where the aim will be to gain an in-depth understanding on how FcRn is regulating transport of engineered IgG antibodies in different types of cells. The agreement is part of the Roche Postdoctoral Fellowship program.

 
 

Alicia Llorente participates in an ERA-NET funded project

 
Alicie Llorente
Alicie Llorente

Alicia Llorente, project group leader at the Department of Molecular Cell Biology in the research group headed by Kirsten Sandvig, has recently received a grant to participate in a project funded by the Horizon2020 action ERA-NET TRANSCAN-2. TRANSCAN-2 is a collaborative network of ministries, funding agencies and research councils that aims to align national/regional translational cancer research programmes.
Both The Norwegian Research Council and The Norwegian Cancer Society participate in TRANSCAN-2. The project is funded by the Third Joint Transnational Call (JTC 2016) dedicated to "Minimally and non-invasive methods for early detection and/or progression of cancer". A total of 14 projects were funded under this call, and three of them have Norwegian participants.